CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
caspofungindrug
Likely dose
Not stated in record
Key inclusion· 2
  • ✓Immunocompromised status from hematologic malignancies, bone marrow failure, HSCT, solid organ transplant, severe neutropenia, HIV, prolonged corticosteroids, other immunosuppressive medications, or other immunocompromising conditions
  • ✓Evidence of proven or probable invasive aspergillosis by modified EORTC criteria
Key exclusion· 4
  • ✕Concomitant use of other systemic antifungal agents
  • ✕Chronic invasive fungal infection (symptoms present >4 weeks before study entry)
  • ✕Prior polyene antifungal therapy ≥4 days within 14 days of enrollment
  • ✕Prior non-polyene antifungal therapy ≥4 days for current documented invasive fungal infection

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00404092
NCT00404092Phase 2Completed
CompareCT.gov

A Phase II Dose Escalation Study of Caspofungin in Patients With Invasive Aspergillosis

University of Cologne·interventional·Posted Nov 27, 2006·Updated Jul 31, 2013

In Brief

A Phase 2 clinical trial evaluating caspofungin for Invasive Aspergillosis. Completed, enrolled 46 participants across 4 sites in 2 countries.

Detailed Summary

This study investigates the safety and tolerability as well as the efficacy and pharmacokinetics of caspofungin in four escalating dosages in adult patients with hematologic malignancies and proven or probable invasive aspergillosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInvasive Aspergillosis
CountriesBelgium, Germany
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 27, 2006
Enrollment StartOct 1, 2006
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 19.6 years ago

Interventions

caspofungindrug

i.v.